3,0
5. Feb. 2017
Aktueller Mitarbeiter, weniger als 1 Jahr
Cambridge, East of England, England
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Great product and opportunity to help prevent morbidity and mortality of patients with CV disease. Company infrastructure us improving but a long way to go. Need better focus.
Kontras
Politics getting in the way of launch plans. Company hires people with expertise, and then Senior Managers who have no experience in the disease area but have longevity start to interfere and try and control the approach in the wrong way.